Loading
Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942.
Jeffrey Weber was principal investigator of CheckMate 238, which showed adjuvant nivolumab beats ipilimumab in resected stage III-IV melanoma with far less toxicity, and of KEYNOTE-942, the randomised trial showing the individualised mRNA neoantigen vaccine mRNA-4157 plus pembrolizumab reduces recurrence versus pembrolizumab alone. He has led immunotherapy development since the interleukin-2 era and directs melanoma research at NYU.
Shares PD-1, Melanoma, Pembrolizumab, Immune checkpoint inhibitors and the tags melanoma, adjuvant.
Shares Stage III melanoma (after surgery), Melanoma and the tags melanoma, adjuvant.
Shares CheckMate 238, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares Ipilimumab, Nivolumab, PD-1, Melanoma and the tag melanoma.
Shares INTerpath-001 (V940-001), Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Intismeran autogene, Stage III melanoma (after surgery), Melanoma.
Shares Stage III melanoma (after surgery), PD-1, Melanoma, Pembrolizumab and the tag melanoma.
Shares Ipilimumab, Nivolumab, PD-1, Melanoma and the tag melanoma.